Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc.

<< Previous

Bullboard Posts

Next >>

Post by Raddnaron Oct 16, 2020 4:16am

312 Views

Post# 31726763

AGN’s Competition Failed Miserably

AGN’s Ifenprodil competitors, Remdesivir and Interferon studied gassed out. Absolutely no positive effect in covid patients.

Ifenprodil is now the leading treatment candidate (always has been imo) in terms of trial pajse progress and Phase 1 (animal study) data. Remember, AGN’s animal study beat Remdesivir by a mile (20% more effective.)

https://www.sciencemag.org/news/2020/10/remdesivir-and-interferon-fall-flat-who-s-megastudy-covid-19-treatments

<< Previous

Bullboard Posts

Next >>

Fobi AI responds to cease trade order, filing delay “disappointing”